Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | E41_L54del |
Impact List | deletion |
Protein Effect | gain of function |
Gene Variant Descriptions | MAP2K1 E41_L54del results in the deletion of 14 amino acids in the Map2k1 protein from amino acids 41 to 54 (UniProt.org). E41_L54del results in increased Map2k1 nuclear localization, elevated Erk phosphorylation, and cell transformation in culture, and promotes tumorigenesis and confers resistance to ROS1 tyrosine kinase inhibitors in the context of a ROS1 fusion (PMID: 32122926). |
Associated Drug Resistance | Y |
Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 E41_L54del |
Transcript | NM_002755.4 |
gDNA | chr15:g.66435067_66435108del42 |
cDNA | c.121_162del42 |
Protein | p.E41_L54del14 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_011521783.3 | chr15:g.66435133_66435174del42 | c.121_162del42 | p.L41_A54del14 | RefSeq | GRCh38/hg38 |
XM_017022413.1 | chr15:g.66481835_66481876del42 | c.121_162del42 | p.D41_M54del14 | RefSeq | GRCh38/hg38 |
NM_001411065.1 | chr15:g.66435133_66435174del42 | c.121_162del42 | p.L41_A54del14 | RefSeq | GRCh38/hg38 |
XM_011521783.4 | chr15:g.66435133_66435174del42 | c.121_162del42 | p.L41_A54del14 | RefSeq | GRCh38/hg38 |
XM_017022411 | chr15:g.66435067_66435108del42 | c.121_162del42 | p.E41_L54del14 | RefSeq | GRCh38/hg38 |
NM_002755.4 | chr15:g.66435067_66435108del42 | c.121_162del42 | p.E41_L54del14 | RefSeq | GRCh38/hg38 |
NM_002755.3 | chr15:g.66435067_66435108del42 | c.121_162del42 | p.E41_L54del14 | RefSeq | GRCh38/hg38 |
NM_002755 | chr15:g.66435067_66435108del42 | c.121_162del42 | p.E41_L54del14 | RefSeq | GRCh38/hg38 |
XM_017022413 | chr15:g.66481835_66481876del42 | c.121_162del42 | p.D41_M54del14 | RefSeq | GRCh38/hg38 |
XM_017022412.1 | chr15:g.66435133_66435174del42 | c.121_162del42 | p.L41_A54del14 | RefSeq | GRCh38/hg38 |
XM_017022411.2 | chr15:g.66435067_66435108del42 | c.121_162del42 | p.E41_L54del14 | RefSeq | GRCh38/hg38 |
XM_011521783 | chr15:g.66435133_66435174del42 | c.121_162del42 | p.L41_A54del14 | RefSeq | GRCh38/hg38 |
XM_017022411.3 | chr15:g.66435067_66435108del42 | c.121_162del42 | p.E41_L54del14 | RefSeq | GRCh38/hg38 |
XM_017022412 | chr15:g.66435133_66435174del42 | c.121_162del42 | p.L41_A54del14 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 E41_L54del | lung cancer | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited growth of transformed human lung cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926). | 32122926 |
MAP2K1 E41_L54del | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited growth of transformed cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926). | 32122926 |
MAP2K1 E41_L54del | lung cancer | sensitive | Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Koselugo (selumetinib) inhibited growth of transformed human lung cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926). | 32122926 |
MAP2K1 E41_L54del | Advanced Solid Tumor | sensitive | Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Koselugo (selumetinib) inhibited growth of transformed cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926). | 32122926 |
MAP2K1 E41_L54del | lung cancer | sensitive | Cobimetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Cotellic (cobimetinib) inhibited growth of transformed human lung cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926). | 32122926 |
MAP2K1 E41_L54del | Advanced Solid Tumor | sensitive | Cobimetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Cotellic (cobimetinib) inhibited growth of transformed cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926). | 32122926 |
MAP2K1 E41_L54del | lung cancer | no benefit | LY3009120 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human lung cells expressing MAP2K1 E41_L54del were not sensitive to LY3009120 in culture (PMID: 32122926). | 32122926 |
MAP2K1 E41_L54del | Advanced Solid Tumor | no benefit | LY3009120 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing MAP2K1 E41_L54del were not sensitive to LY3009120 in culture (PMID: 32122926). | 32122926 |